Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

被引：0

作者：

Narezkina, Anna ^{[1
]}

Akhter, Nausheen ^{[2
]}

Lu, Xiaoxiao ^{[3
]}

Emond, Bruno ^{[4
]}

Huang, Qing ^{[3
]}

Panjabi, Sumeet ^{[3
]}

Hilts, Annalise ^{[4
]}

Lu, Stephanie ^{[5
]}

Lafeuille, Helene ^{[4
]}

Lafeuille, Marie-Helene ^{[4
]}

Choi, Michael ^{[6
]}

机构：

[1] Univ Calif San Diego Hlth, San Diego, CA USA

[2] Northwestern Med, Chicago, IL USA

[3] Janssen Sci Affairs LLC, Horsham, PA USA

[4] Anal Grp Inc, Montreal, PQ, Canada

[5] Anal Grp Inc, Menlo Pk, CA USA

[6] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷

关键词：

CLL; chronic lymphocytic leukemia/small lymphocytic lymphoma; Bruton's tyrosine kinase inhibitor; time to next treatment; treatment persistence; atrial fibrillation;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CLL-390

引用

页码：S276 / S277

页数：2

共 50 条

[11] Risk of stroke in patients with atrial fibrillation and chronic lymphocytic leukemia
Yetiskul, Ekrem
Rizvi, Taqi
Khan, Shahkar
Khan, Salman
Alomari, Omer
Agarwal, Alaukika
Asmar, Samer
Sah, Sajan
Khattar, Georges
Grabie, Yisroel
Saliba, Fares
Matra, Amanda Marie
Mokhtar, Asmaa
Dhar, Meekoo
Bershadskiy, Alexander
Khan, Danyal F.
Mustafa, Ahmad
Spagnola, Jonathan
Parikh, Valay K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[12] Real-World Effectiveness and Safety Outcomes of Acalabrutinib Treatment By Line of Therapy in Patients with Chronic Lymphocytic Leukemia and/or Small Lymphocytic Lymphoma
Jacobs, Ryan W.
Teschemaker, Anna
Hakre, Shweta
Tian, Hongping
Pyrih, Nick
Wahlstrom, Svea K.
Cui, Lianzhou
BLOOD, 2023, 142
[13] Real-World Characterization of Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) Patients in British Columbia (BC)
Khelifi, Rania S.
Huang, Steven J. T.
Savage, Kerry J.
Villa, Diego
Scott, David W.
Ramadan, Khaled
Connors, Joseph M.
Sehn, Laurie H.
Toze, Cynthia L.
Gerrie, Alina S.
BLOOD, 2020, 136
[14] Phase I study of ibrutinib in Japanese patients with treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma
Shibayama, Hirohiko
Teshima, Takanori
Choi, Ilseung
Hatake, Kiyohiko
Sekiguchi, Naohiro
Yoshinari, Nozomi
JOURNAL OF CLINICAL AND EXPERIMENTAL HEMATOPATHOLOGY, 2019, 59 (04) : 179 - 186
[15] Ibrutinib in Treatment of Patients with chronic lymphocytic Leukemia
Flammiger, A.
ONKOLOGE, 2015, 21 (08): : 732 - 733
[16] REAL-WORLD ECONOMIC OUTCOMES OF FIRST-LINE (1L) IBRUTINIB TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
Challagulla, S.
Lee, P.
Kistler, K.
Douyon, L.
Lai, D.
Iyengar, R.
VALUE IN HEALTH, 2021, 24 : S38 - S38
[17] Time to Next Treatment, Healthcare Resource Utilization, and Healthcare Costs Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following FirstLine Ibrutinib
Challagulla, Swetha
Emond, Bruno
Volodarsky, Raisa R.
Young, Alex
Manceur, Ameur
Karve, Sudeep
BLOOD, 2021, 138
[18] Combined Ibrutinib and Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Awan, Farrukh T.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 13 - 14
[19] Real-world treatment patterns and characteristics in patients with chronic lymphocytic leukemia
Schenkel, Brad
Rider, Alex
Macomson, Brian
Hallworth, Pam
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (08)
[20] NURSING EXPERIENCE WITH THE USE OF IBRUTINIB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA
Haycraft, Dana
O'Mary, Sharon
Hsu, Emily
Arthur, David
Kipps, Thomas
Stevens, Don
ONCOLOGY NURSING FORUM, 2021, 48 (02)

← 1 2 3 4 5 →